Jingan Lou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jingan Lou has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Jie Chen
Gastroenterology Department, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China
4 shared publications - Youyou Luo
Children’s Hospital, National Clinical Research Center for Children and Adolescents’ Health and Diseases, Zhejiang University School of Medicine, Hangzhou, China
4 shared publications Hong Zhao
Gastroenterology, Zhejiang University School of Medicine Children’s Hospital, Hangzhou, China
3 shared publications- Youhong Fang
Department of Gastroenterology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China
3 shared publications - Jindan Yu
Gastroenterology Department
2 shared publications - Jindan Yu
Department of Gastroenterology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China
2 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Elsevier in Jornal de Pediatria
- Vol. 102 (4) , 101553
Characteristics of patients with neonatal intrahepatic cholestasis caused by citrin deficiency in China: long-term follow-up outcomes
- 19 May 2026
- Published by Elsevier in Jornal de Pediatria
- Vol. 102 (4) , 101553
Open AccessCharacteristics of patients with neonatal intrahepatic cholestasis caused by citrin deficiency in China: long-term follow-up outcomes
- Open Access
- 6 February 2026
- Published by Elsevier in Jornal de Pediatria
- Vol. 102 (2) , 101501
The utilization of oral feeding in pediatric pancreatitis: a randomized controlled study
- 6 February 2026
- Published by Elsevier in Jornal de Pediatria
- Vol. 102 (2) , 101501
Open AccessThe utilization of oral feeding in pediatric pancreatitis: a randomized controlled study
- Open Access
- 9 January 2024
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 56 (S 01) , E408-E409
Use of biliopancreatic duct imaging system in a 13-month-old girl to enable endoscopic removal of a foreign body in the appendix
A 13-month-old girl was admitted because of the observation over a month previously of a screw-like foreign body in the right lower quadrant. The patient was asymptomatic; physical examination showed normal findings. After admission, an X-ray showed a screw in the right lower quadrant ([Fig. 1]). Our initial attempts to find the object by colonoscopy failed. Subsequently, a foreign body in the appendix was suspected, and ultrasound examination confirmed that this was indeed the case ([Fig. 2]). After communication with the parents, they were first referred to endoscopic treatment for the child. Endoscopic treatment was performed under anesthesia with endotracheal intubation. We used a colonoscope with a clear cap (H290I; Olympus, Tokyo, Japan) to intubate the cecum and observe the appendiceal orifice, which we found to be smooth. Subsequently, we inserted a disposable biliopancreatic duct imaging catheter (DPIC, D-000021494; Micro-Tech, Nanjing, China) into the appendiceal orifice and, after irrigation, found the screw deep in the appendix. Finally, we used a spiral stone extraction basket (CEB00000; Nanjing Weike Technology, China) to remove the screw ([Video 1], [Fig. 3], [Fig. 4]). The patient had no postoperative complications and was discharged 2 days later. Appendiceal foreign bodies in children are very rare. The largest series, reported by Fuller et al., showed that hair and plant material were the most common foreign objects found in the appendix [1]. Appendiceal foreign bodies in children are sometimes asymptomatic; however, they may lead to perforation, secondary appendiceal abscess and abdominal infection [2] [3]. The appendiceal cavity in children is very narrow; it is difficult for foreign bodies to be expelled spontaneously once they enter into the appendix, except in a few cases [4]. To the best of our knowledge, our patient is the youngest and lightest patient in whom a biliopancreatic duct imaging system was used to enable endoscopic retrograde treatment for an appendiceal foreign body. Endoscopy_UCTN_Code_TTT_1AQ_2AH Article published online: 17 May 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 9 January 2024
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 56 (S 01) , E408-E409
Open AccessUse of biliopancreatic duct imaging system in a 13-month-old girl to enable endoscopic removal of a foreign body in the appendix
A 13-month-old girl was admitted because of the observation over a month previously of a screw-like foreign body in the right lower quadrant. The patient was asymptomatic; physical examination showed normal findings. After admission, an X-ray showed a screw in the right lower quadrant ([Fig. 1]). Our initial attempts to find the object by colonoscopy failed. Subsequently, a foreign body in the appendix was suspected, and ultrasound examination confirmed that this was indeed the case ([Fig. 2]). After communication with the parents, they were first referred to endoscopic treatment for the child. Endoscopic treatment was performed under anesthesia with endotracheal intubation. We used a colonoscope with a clear cap (H290I; Olympus, Tokyo, Japan) to intubate the cecum and observe the appendiceal orifice, which we found to be smooth. Subsequently, we inserted a disposable biliopancreatic duct imaging catheter (DPIC, D-000021494; Micro-Tech, Nanjing, China) into the appendiceal orifice and, after irrigation, found the screw deep in the appendix. Finally, we used a spiral stone extraction basket (CEB00000; Nanjing Weike Technology, China) to remove the screw ([Video 1], [Fig. 3], [Fig. 4]). The patient had no postoperative complications and was discharged 2 days later. Appendiceal foreign bodies in children are very rare. The largest series, reported by Fuller et al., showed that hair and plant material were the most common foreign objects found in the appendix [1]. Appendiceal foreign bodies in children are sometimes asymptomatic; however, they may lead to perforation, secondary appendiceal abscess and abdominal infection [2] [3]. The appendiceal cavity in children is very narrow; it is difficult for foreign bodies to be expelled spontaneously once they enter into the appendix, except in a few cases [4]. To the best of our knowledge, our patient is the youngest and lightest patient in whom a biliopancreatic duct imaging system was used to enable endoscopic retrograde treatment for an appendiceal foreign body. Endoscopy_UCTN_Code_TTT_1AQ_2AH Article published online: 17 May 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 2 September 2022
- Published by Wiley in Gastroenterology Research and Practice
- Vol. 2022, 1-9
Outcomes of Pediatric Patients with Crohn’s Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission
Background. Both exclusive enteral nutrition (EEN) and infliximab (IFX) are recommended as induction therapy for pediatric Crohns disease (CD). Our aim was to compare long-term disease outcomes of patients initially received with either IFX or EEN. Methods. Medical records of newly diagnosed, therapy nave pediatric patients with CD received with IFX or EEN as induction therapy were retrospectively enrolled. Pediatric Crohns disease activity index (PCDAI), Crohns disease endoscopic index of severity (CDEIS), and other clinical data were compared pre- and postinduction therapy in two groups. The sustained remission rates and time coupled with body mass index (BMI) and height for age (HFA) changes were evaluated during more than 2-year long-term follow-up. Results. We collected data from 58 children with CD used IFX (23) or EEN (35) as induction remission therapy from January 2015 through June 2021 in our single-center. The median follow-up after starting IFX or EEN was 12.2 months (6.518.0months) and 18.9 months (7.130.7months), respectively. The proportion clinical and endoscopic remission in EEN (88.57 and 68.75) was similar with that of IFX (73.91 and 80.77) after induction therapy. No significant differences were also observed in BMI and HFA recovery between two groups. Among those who achieved clinical or endoscopic remission or endoscopic response, the sustained remission rates and time did not reveal any significant differences for those 10 patients who used 6-mercaptopurine/methotrexate (6-MP/MTX) or 14 patients who used IFX as maintenance treatment during longitudinal follow-up. Conclusions. Our study suggested that EEN treatment is similar with IFX therapy in short-term outcomes, and EEN+6-MP/MTX treatment is comparable with IFX+IFX therapy in long-term outcomes.
- 2 September 2022
- Published by Wiley in Gastroenterology Research and Practice
- Vol. 2022, 1-9
Open AccessOutcomes of Pediatric Patients with Crohn’s Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission
Background. Both exclusive enteral nutrition (EEN) and infliximab (IFX) are recommended as induction therapy for pediatric Crohns disease (CD). Our aim was to compare long-term disease outcomes of patients initially received with either IFX or EEN. Methods. Medical records of newly diagnosed, therapy nave pediatric patients with CD received with IFX or EEN as induction therapy were retrospectively enrolled. Pediatric Crohns disease activity index (PCDAI), Crohns disease endoscopic index of severity (CDEIS), and other clinical data were compared pre- and postinduction therapy in two groups. The sustained remission rates and time coupled with body mass index (BMI) and height for age (HFA) changes were evaluated during more than 2-year long-term follow-up. Results. We collected data from 58 children with CD used IFX (23) or EEN (35) as induction remission therapy from January 2015 through June 2021 in our single-center. The median follow-up after starting IFX or EEN was 12.2 months (6.518.0months) and 18.9 months (7.130.7months), respectively. The proportion clinical and endoscopic remission in EEN (88.57 and 68.75) was similar with that of IFX (73.91 and 80.77) after induction therapy. No significant differences were also observed in BMI and HFA recovery between two groups. Among those who achieved clinical or endoscopic remission or endoscopic response, the sustained remission rates and time did not reveal any significant differences for those 10 patients who used 6-mercaptopurine/methotrexate (6-MP/MTX) or 14 patients who used IFX as maintenance treatment during longitudinal follow-up. Conclusions. Our study suggested that EEN treatment is similar with IFX therapy in short-term outcomes, and EEN+6-MP/MTX treatment is comparable with IFX+IFX therapy in long-term outcomes.
- Open Access
60-nt DNA Direct Detection without Pretreatment by Surface-Enhanced Raman Scattering with Polycationic Modified Ag Microcrystal Derived from AgCl Cube
Direct detection of long-strand DNA by surface-enhanced Raman scattering (SERS) is a valuable method for diagnosis of hereditary diseases, but it is currently limited to less than 25-nt DNA strand in pure water, which makes this approach unsuitable for many real-life applications. Here, we report a 60-nt DNA label-free detection strategy without pretreatment by SERS with polyquaternium-modified Ag microcrystals derived from an AgCl cube. Through the reduction-induced decomposition, the size of the about 3 × 3 × 3 μm3 AgCl cube is reduced to Ag, and the surface is distributed with the uniform size of 63 nm silver nanoparticles, providing a large area of a robust and highly electromagnetic enhancement region. The modified polycationic molecule enhances the non-specific electrostatic interaction with the phosphate group, thereby anchoring DNA strands firmly to the SERS enhanced region intactly. As a result, the single-base recognition ability of this strategy reaches 60-nt and is successfully applied to detect thalassemia-related mutation genes.
Open Access60-nt DNA Direct Detection without Pretreatment by Surface-Enhanced Raman Scattering with Polycationic Modified Ag Microcrystal Derived from AgCl Cube
Direct detection of long-strand DNA by surface-enhanced Raman scattering (SERS) is a valuable method for diagnosis of hereditary diseases, but it is currently limited to less than 25-nt DNA strand in pure water, which makes this approach unsuitable for many real-life applications. Here, we report a 60-nt DNA label-free detection strategy without pretreatment by SERS with polyquaternium-modified Ag microcrystals derived from an AgCl cube. Through the reduction-induced decomposition, the size of the about 3 × 3 × 3 μm3 AgCl cube is reduced to Ag, and the surface is distributed with the uniform size of 63 nm silver nanoparticles, providing a large area of a robust and highly electromagnetic enhancement region. The modified polycationic molecule enhances the non-specific electrostatic interaction with the phosphate group, thereby anchoring DNA strands firmly to the SERS enhanced region intactly. As a result, the single-base recognition ability of this strategy reaches 60-nt and is successfully applied to detect thalassemia-related mutation genes.
- 12 July 2021
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 17 (5) , 536-543
Nasogastric or nasojejunal feeding in pediatric acute pancreatitis: a randomized controlled trial
Background The aim of this study was to compare nasogastric (NG) feeding with nasojejunal (NJ) feeding when treating pediatric patients with acute pancreatitis (AP). Methods We performed a single-center, prospective, randomized, active-controlled trial involving 77 pediatric patients with AP from April 2014 to December 2017. The patients were randomized into two groups: the NG tube feeding group (34 patients) and the NJ tube feeding group (33 patients). The primary outcome measures included the enteral nutrition intolerance, the length of tube feeding time, the recurrent pain of pancreatitis and complications. Results A total of 62 patients with AP (31 patients for each group) came into the final analysis. No differences were found in baseline characteristics, pediatric AP score and computed tomography severity score between the two groups. Three (9.7%) patients in the NG group and one (3.2%) patient in the NJ group developed intolerance (relative risk = 3.00, 95% confidence interval 0.33–27.29, P = 0.612). The tube feeding time and length of hospital stay of the NG group were significantly shorter than those of the NJ group (P = 0.016 and 0.027, respectively). No patient died in the trial. No significant differences were found in recurrent pain, complications, nutrition delivery efficacy, and side effects between the two groups. Conclusions NG tube feeding appears to be effective and safe for acute pediatric pancreatitis compared with NJ tube feeding. In addition, high qualified, large sample sized, randomized controlled trials in pediatric population are needed.
- 12 July 2021
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 17 (5) , 536-543
Nasogastric or nasojejunal feeding in pediatric acute pancreatitis: a randomized controlled trial
Background The aim of this study was to compare nasogastric (NG) feeding with nasojejunal (NJ) feeding when treating pediatric patients with acute pancreatitis (AP). Methods We performed a single-center, prospective, randomized, active-controlled trial involving 77 pediatric patients with AP from April 2014 to December 2017. The patients were randomized into two groups: the NG tube feeding group (34 patients) and the NJ tube feeding group (33 patients). The primary outcome measures included the enteral nutrition intolerance, the length of tube feeding time, the recurrent pain of pancreatitis and complications. Results A total of 62 patients with AP (31 patients for each group) came into the final analysis. No differences were found in baseline characteristics, pediatric AP score and computed tomography severity score between the two groups. Three (9.7%) patients in the NG group and one (3.2%) patient in the NJ group developed intolerance (relative risk = 3.00, 95% confidence interval 0.33–27.29, P = 0.612). The tube feeding time and length of hospital stay of the NG group were significantly shorter than those of the NJ group (P = 0.016 and 0.027, respectively). No patient died in the trial. No significant differences were found in recurrent pain, complications, nutrition delivery efficacy, and side effects between the two groups. Conclusions NG tube feeding appears to be effective and safe for acute pediatric pancreatitis compared with NJ tube feeding. In addition, high qualified, large sample sized, randomized controlled trials in pediatric population are needed.
- 16 November 2020
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 66 (10) , 3555-3562
Infliximab Therapy in Very Early Onset Crohn’s Disease: Real-World Experience in China
Background Data concerning of the effectiveness of infliximab in very early onset Crohn’s disease patients are rare. Aim To assess the effectiveness and safety issues of infliximab treatment for this rare cohort. Methods The pediatric Crohn’s disease activity index, Crohn’s disease endoscopic index score, height, and weight were retrospectively recorded at baseline, week 14, and week 54. The rates of clinical remission and mucosal healing and growth of patients were compared between patients younger and older than 6 years of age. Loss of response or non-response to infliximab and adverse events were assessed during the entire treatment period. Results Sixty-five patients were enrolled in the study. Sixty-four percent and 40.0% of very early onset Crohn’s disease patients achieved clinical remission and mucosal healing after induction therapy. Adjusted for the covariances, very early disease onset had no association with primary non-response (p = 0.360) or mucosal healing (p = 0.361). Early disease onset was associated with discontinuation of infliximab due to adverse events (hazard ratio [HR] 7.15, 95% CI 1.73–29.51, p = 0.006). Patients < 6 years had lower body mass index for age z score improvement during the induction phase (p = 0.04). Conclusions Very early onset Crohn’s disease patients had similar non-response rates and mucosal healing rates as those who were 6 years or older during induction therapy. Greater discontinuation of infliximab due to adverse events was observed in very early onset Crohn’s disease patients.
- 16 November 2020
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 66 (10) , 3555-3562
Infliximab Therapy in Very Early Onset Crohn’s Disease: Real-World Experience in China
Background Data concerning of the effectiveness of infliximab in very early onset Crohn’s disease patients are rare. Aim To assess the effectiveness and safety issues of infliximab treatment for this rare cohort. Methods The pediatric Crohn’s disease activity index, Crohn’s disease endoscopic index score, height, and weight were retrospectively recorded at baseline, week 14, and week 54. The rates of clinical remission and mucosal healing and growth of patients were compared between patients younger and older than 6 years of age. Loss of response or non-response to infliximab and adverse events were assessed during the entire treatment period. Results Sixty-five patients were enrolled in the study. Sixty-four percent and 40.0% of very early onset Crohn’s disease patients achieved clinical remission and mucosal healing after induction therapy. Adjusted for the covariances, very early disease onset had no association with primary non-response (p = 0.360) or mucosal healing (p = 0.361). Early disease onset was associated with discontinuation of infliximab due to adverse events (hazard ratio [HR] 7.15, 95% CI 1.73–29.51, p = 0.006). Patients < 6 years had lower body mass index for age z score improvement during the induction phase (p = 0.04). Conclusions Very early onset Crohn’s disease patients had similar non-response rates and mucosal healing rates as those who were 6 years or older during induction therapy. Greater discontinuation of infliximab due to adverse events was observed in very early onset Crohn’s disease patients.
- Open Access
- 15 June 2018
- Published by Springer Nature in BMC Pediatrics
- Vol. 18 (1) , 191
A case of Metaplastic atrophic gastritis in immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) syndrome
Autoimmune metaplastic atrophic gastritis is a chronic progressive inflammatory condition. The clinical spectrum includes pernicious anemia, atrophic gastritis, antibodies to parietal cell antigens and intrinsic factor, achlorhydria, hypergastrinemia and carcinoma. It is rare in paediatric cohorts. We present the case of a boy with metaplastic atrophic gastritis in whom immune dysregulation, polyendocrinopathy, enteropathy, X-linked(IPEX) syndrome was confirmed by FOXP3 gene mutation. The patient was referred to the hospital at the age of 3 years with recurrent emesis, diarrhoea and malnutrition. His elder brother died at 9 years of age from acute respiratory distress syndrome and renal tubular acidosis. The patient was allergic to cow milk formula and noodles. Oesophagegastroduodenoscopy revealed redness, erosion and edema throughout the stomach; whitish granules in the duodenal bulb; and edema in the second part of the duodenum. Biopsies showed extensive villous atrophy and goblet cell depletion in the duodenum. He was diagnosed with type-1 diabetes mellitus (T1DM) during the treatment of methylprednisolone. Serum antibodies against glutamic acid decarboxylase and pancreatic islets were detected. The patient’s FOXP3 gene was sequenced; this identified that the patient was hemizygous for a pathogenic variant [NM_014009.3:c.748_750del (p.Lys250del)]. Metaplastic atrophic gastritis is rarely reported in patients with IPEX. Clinical gastroenterologists should be aware of IPEX syndrome when facing the complex syndromes of metaplastic atrophic gastritis and endocrinopathy.
- 15 June 2018
- Published by Springer Nature in BMC Pediatrics
- Vol. 18 (1) , 191
Open AccessA case of Metaplastic atrophic gastritis in immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) syndrome
Autoimmune metaplastic atrophic gastritis is a chronic progressive inflammatory condition. The clinical spectrum includes pernicious anemia, atrophic gastritis, antibodies to parietal cell antigens and intrinsic factor, achlorhydria, hypergastrinemia and carcinoma. It is rare in paediatric cohorts. We present the case of a boy with metaplastic atrophic gastritis in whom immune dysregulation, polyendocrinopathy, enteropathy, X-linked(IPEX) syndrome was confirmed by FOXP3 gene mutation. The patient was referred to the hospital at the age of 3 years with recurrent emesis, diarrhoea and malnutrition. His elder brother died at 9 years of age from acute respiratory distress syndrome and renal tubular acidosis. The patient was allergic to cow milk formula and noodles. Oesophagegastroduodenoscopy revealed redness, erosion and edema throughout the stomach; whitish granules in the duodenal bulb; and edema in the second part of the duodenum. Biopsies showed extensive villous atrophy and goblet cell depletion in the duodenum. He was diagnosed with type-1 diabetes mellitus (T1DM) during the treatment of methylprednisolone. Serum antibodies against glutamic acid decarboxylase and pancreatic islets were detected. The patient’s FOXP3 gene was sequenced; this identified that the patient was hemizygous for a pathogenic variant [NM_014009.3:c.748_750del (p.Lys250del)]. Metaplastic atrophic gastritis is rarely reported in patients with IPEX. Clinical gastroenterologists should be aware of IPEX syndrome when facing the complex syndromes of metaplastic atrophic gastritis and endocrinopathy.